Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
May 02 11:24AM ET
15.76
Dollar change
+0.09
Percentage change
0.55
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y-8.50% Shs Outstand Perf Week4.02%
SponsorWisdom Tree ETF Type Tagsequity Return% 3Y- Total Holdings99 Perf Month-5.25%
Fund Family Bond Type Tagsbiotechnology Return% 5Y- AUM2.35M Perf Quarter-2.51%
IndexWisdomTree BioRevolution Index Average Maturity Tags- Return% 10Y NAV% Perf Half Y15.39%
Index Weighting Commodity Type Tags- Return% SI NAV/sh Perf Year-7.78%
Active/Passive Quant Type Tags- Flows% 1M0.00% 52W Range13.37 - 18.52 Perf YTD-6.55%
Dividend TTM0.14 (0.86%) ESG Type Tags- Flows% 3M-6.62% 52W High-14.92% Beta1.04
Dividend Ex-DateDec 22, 2023 Dividend Type Sector/Theme Flows% YTD-6.62% 52W Low17.84% ATR (14)0.26
Expense0.45% Structure Type Region Flows% 1Y RSI (14)47.67 Volatility0.92% 0.80%
Option/ShortYes / Yes Growth/Value Dev/Emerg Flows% 3Y Rel Volume2.06 Prev Close15.67
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume1.33K Price15.76
SMA200.08% SMA50-4.74% SMA200-2.12% Trades Volume1,135 Change0.55%
WisdomTree BioRevolution Fund seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index ("index"). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.